A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni Ryan Abdul Razak,James M. Cleary,Victor Moreno,Michael Boyer,Emilliano Calvo Aller,William Jeffery Edenfield,Jeanne Tie,R. Donald Harvey,Annemie Rutten,Manish A. Shah,Anthony J. Olszanski,Dirk Jäger,Nehal Lakhani,David P. Ryan,Erik Rasmussen,Gloria Juan,Hansen Wong,Neelesh Soman,Marie-Anne Damiette Smit,Dirk Nagorsen,Kyriakos P. Papadopoulos +20 more
TL;DR: The recommended combination dose of 1100 mg AMG 820 plus 200 mg pembrolizumab had an acceptable safety profile and antitumor activity was insufficient for further evaluation of this combination in selected patient populations.
Journal ArticleDOI
Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft Part Sarcoma
Jeremy Lewin,Scott Davidson,Nathaniel D. Anderson,Beatrice Y. Lau,Jacalyn Kelly,Uri Tabori,Samer Salah,Marcus O. Butler,Kyaw L. Aung,Adam Shlien,Brendan C. Dickson,Albiruni Ryan Abdul Razak +11 more
TL;DR: Sustained partial responses in two patients with immune checkpoint inhibition treated with either durvalumab alone or in combination with tremelimumab (anti–CTLA-4), which appeared unrelated to tumor immune infiltrates or mutational burden suggest that immune checkpoint blockade may be a useful therapeutic strategy for ASPS.
Journal ArticleDOI
Survival outcomes for cutaneous angiosarcoma of the scalp versus face
Jonathan M. Bernstein,Jonathan C. Irish,Dale H. Brown,David P. Goldstein,Peter Chung,Albiruni Ryan Abdul Razak,Charles Catton,Ralph W. Gilbert,Patrick J. Gullane,Brian O'Sullivan +9 more
TL;DR: The primary purpose of this study was to examine whether angiosarcoma outcomes differ for the scalp and face.
Journal ArticleDOI
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies
Maja J.A. de Jonge,Neeltje Steeghs,Martijn P. Lolkema,Martijn P. Lolkema,Sebastien J. Hotte,Hal W. Hirte,Diane A.J. van der Biessen,Albiruni Ryan Abdul Razak,Filip de Vos,Remy B. Verheijen,David Schnell,Linda C Pronk,Monique Jansen,Lillian L. Siu +13 more
TL;DR: BI 853520 has a manageable and acceptable safety profile, favorable PK, and modest antitumor activity at an MTD of 200 mg once daily (QD) in patients with selected advanced nonhematologic malignancies.
Journal ArticleDOI
Tumor necrosis and clinical outcomes following neoadjuvant therapy in soft tissue sarcoma: A systematic review and meta-analysis.
TL;DR: Tumour necrosis <90% following neoadjuvant therapy is associated with increased recurrence risk and inferior OS in patients with STS, and ILP was associated with higher odds of achieving ≥90% necrosis.